Galectin Therapeutics (GALT) Equity Ratio (2010 - 2026)

Galectin Therapeutics' Equity Ratio history runs 17 years deep, the most recent figure standing at 8.37 for Q1 2026.

• In Q1 2026, Equity Ratio rose 30.0% year-over-year to 8.37; the TTM figure through Mar 2026 stood at 8.37 (up 30.0% YoY), while the FY2025 annual figure was 6.55, down 9.34% from the prior year.
• Equity Ratio was 8.37 for Q1 2026 at Galectin Therapeutics, down from 6.55 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.24 in Q1 2022 to a low of 11.96 in Q1 2025.
• Historically, Equity Ratio has averaged 4.2 across 5 years, with a median of 2.63 in 2023.
• The sharpest annual moves came in 2022 and 2026: Equity Ratio slumped 7563.61% in 2022, then jumped 30.0% in 2026.
• A 5-year view of Equity Ratio shows it stood at 1.59 in 2022, then tumbled by 37.89% to 2.2 in 2023, then slumped by 172.6% to 5.99 in 2024, then declined by 9.34% to 6.55 in 2025, then dropped by 27.86% to 8.37 in 2026.
• The last three Equity Ratio figures came in at 8.37 (Q1 2026), 6.55 (Q4 2025), and 9.74 (Q3 2025), per Business Quant data.